Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients.
c-reactive protein
crp
il-6
inflammatory markers
interleukin-6
major depression
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
11 Jan 2019
11 Jan 2019
Historique:
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Background Major depressive disorder (MDD) is a disabling health problem with a very high global prevalence and burden. Alteration of inflammatory markers in depression is of growing interest to many psychiatry researchers. This study aimed to examine the serum levels of interleukin-6 (IL-6) and C-reactive protein (CRP) in MDD patients to find out their association with depression. Materials and methods The present study recruited 88 MDD patients and 86 control subjects matched by age, gender, and body mass index (BMI). The Hamilton depression rating scale (Ham-D) was used on all patients to measure their severity of depression. Serum levels of IL-6 and CRP were analyzed by commercially available enzyme-linked immunosorbent assay (ELISA) kits (Abcam, Cambridge, MA, USA). Results The mean values of serum levels of IL-6 and CRP were 2.94 ± 0.12 pg/mL and 0.99 ± 0.02 mg/L for the patient group and 2.42 ± 0.21 pg/mL and 1.09 ± 0.06 mg/L for the control group, respectively. We found significantly elevated concentrations of serum IL-6 in MDD patients compared with control subjects (p < 0.001). However, the alteration of serum CRP levels was not significant between the groups (p = 0.126). Ham-D scores of patients were positively correlated with serum IL-6 (r = 0.552; p = 0.004) and CRP (r = 0.621; p < 0.001) levels. Moreover, serum IL-6 and CRP levels were observed to be positively correlated (r = 0.452; p = 0.043) with each other in depression. Conclusions The present study suggests that increased serum IL-6 level might be a contributing factor to the pathogenesis of depression.
Identifiants
pubmed: 30899619
doi: 10.7759/cureus.3868
pmc: PMC6414189
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e3868Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neurotox Res. 2006 Oct;10(2):131-48
pubmed: 17062375
J Affect Disord. 1995 Aug 18;34(4):301-9
pubmed: 8550956
Mol Psychiatry. 2008 Jul;13(7):717-28
pubmed: 17700577
Metabolism. 2005 May;54(5 Suppl 1):10-5
pubmed: 15877306
Maturitas. 2009 Feb 20;62(2):146-52
pubmed: 19179025
Cureus. 2017 Oct 3;9(10):e1740
pubmed: 29209587
Cytokine. 1997 Nov;9(11):853-8
pubmed: 9367546
Psychiatry Res. 2018 Jun;264:26-30
pubmed: 29626828
Psychiatry Res. 2012 Jun 30;198(1):74-80
pubmed: 22386567
J Affect Disord. 2019 Jan 15;243:70-74
pubmed: 30236760
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:277-84
pubmed: 26111720
SAGE Open Med. 2018 May 09;6:2050312118773953
pubmed: 29770218
Pharmacol Rep. 2018 Dec;70(6):1065-1072
pubmed: 30296742
Pediatr Allergy Immunol. 2012 Dec;23(8):707-15
pubmed: 22957535
Hum Psychopharmacol. 2017 Jul;32(4):
pubmed: 28582802
Vasc Med. 2018 Oct;23(5):445-453
pubmed: 30035700
BMC Psychiatry. 2018 Apr 10;18(1):94
pubmed: 29631563
Mod Trends Pharmacopsychiatry. 2017;31:27-36
pubmed: 28738332
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Psychol Med. 2013 Mar;43(3):471-81
pubmed: 22831756
Psychol Med. 2018 Nov;48(15):2508-2514
pubmed: 29415791
East Asian Arch Psychiatry. 2018 Jun;28(2):53-58
pubmed: 29921741
Adv Exp Med Biol. 1999;461:317-29
pubmed: 10442180
Psychosom Med. 2018 Feb/Mar;80(2):167-173
pubmed: 29016549
Psychiatry Res. 2017 Jun;252:270-276
pubmed: 28285256
Sci Rep. 2018 Aug 13;8(1):12050
pubmed: 30104698